Galmed Pharmaceuticals Company Profile (NASDAQ:GLMD)

About Galmed Pharmaceuticals

Galmed Pharmaceuticals logoGalmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product candidate, aramchol, is a disease modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis (NASH). The Company's Aramchol is a conjugate of cholic acid and arachidic acid, which is a member of synthetic Fatty-Acid/Bile-Acid Conjugates (FABACs). FABACs are composed of endogenic compounds. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis (NASH). Aramchol is in Phase IIb clinical trials.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: GLMD
  • CUSIP:
Key Metrics:
  • Previous Close: $4.91
  • 50 Day Moving Average: $4.09
  • 200 Day Moving Average: $4.69
  • 52-Week Range: $3.50 - $10.20
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.90
  • P/E Growth: 0.00
  • Market Cap: $54.51M
  • Outstanding Shares: 11,102,000
  • Beta: 2.22
Profitability:
  • Return on Equity: -71.48%
  • Return on Assets: -62.73%
Debt:
  • Current Ratio: 5.12%
  • Quick Ratio: 5.12%
Additional Links:
Companies Related to Galmed Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Galmed Pharmaceuticals (NASDAQ:GLMD) (?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $14.25 (190.22% upside)

Analysts' Ratings History for Galmed Pharmaceuticals (NASDAQ:GLMD)
Show:
DateFirmActionRatingPrice TargetDetails
8/5/2016FBR & CoSet Price TargetBuy$20.00View Rating Details
8/1/2016Maxim GroupReiterated RatingBuy$24.00 -> $9.00View Rating Details
7/6/2016Roth CapitalReiterated RatingBuy$6.00View Rating Details
6/30/2016HC WainwrightReiterated RatingBuyView Rating Details
8/19/2015MLV & Co.Reiterated RatingBuy$24.00View Rating Details
8/14/2015SunTrust Banks Inc.Lower Price TargetBuy$20.00 -> $19.00View Rating Details
(Data available from 9/28/2014 forward)

Earnings

Earnings History for Galmed Pharmaceuticals (NASDAQ:GLMD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2016        
8/3/2016Q216($0.35)($0.39)ViewN/AView Earnings Details
5/16/2016Q116($0.33)($0.36)ViewListenView Earnings Details
3/22/2016Q415($0.28)($0.29)ViewListenView Earnings Details
11/9/2015Q315($0.29)($0.23)ViewN/AView Earnings Details
8/13/2015Q215($0.28)($0.21)ViewListenView Earnings Details
5/13/2015Q1($0.26)($0.22)ViewListenView Earnings Details
3/31/2015($0.36)($0.15)ViewN/AView Earnings Details
11/12/2014Q314($0.37)($0.62)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Galmed Pharmaceuticals (NASDAQ:GLMD)
Current Year EPS Consensus Estimate: $-1.51 EPS
Next Year EPS Consensus Estimate: $-1.26 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.32)($0.32)($0.32)
Q2 20163($0.41)($0.26)($0.35)
Q3 20163($0.44)($0.28)($0.37)
Q4 20163($0.39)($0.30)($0.34)
Q1 20171($0.29)($0.29)($0.29)
Q2 20171($0.29)($0.29)($0.29)
Q3 20171($0.21)($0.21)($0.21)
Q4 20171($0.21)($0.21)($0.21)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Galmed Pharmaceuticals (NASDAQ:GLMD)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Galmed Pharmaceuticals (NASDAQ:GLMD)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Galmed Pharmaceuticals (NASDAQ:GLMD)
DateHeadline
finance.yahoo.com logoGalmed Pharmaceuticals and the University of California, San Diego Enter into an Investigator-Initiated … (NASDAQ:GLMD)
finance.yahoo.com - September 23 at 4:57 PM
News IconGalmed Pharmaceuticals and the University of California, San Diego Enter into an Investigator-Initiated Clinical Trial Agreem... (NASDAQ:GLMD)
ih.advfn.com - September 23 at 4:57 PM
News IconEye Catching Stocks Gaining Limelight: Microsoft (NASDAQ:MSFT), Galmed Pharmaceuticals (NASDAQ:GLMD ... - Street Wise Report (press release) (blog) (NASDAQ:GLMD)
streetwisereport.com - September 23 at 10:14 AM
streetinsider.com logoGalmed Pharma (GLMD), UCSD Enter Collaboration to Assess Aramchol in Juvenile Population - StreetInsider.com (NASDAQ:GLMD)
www.streetinsider.com - September 22 at 5:20 PM
News IconGalmed Pharmaceuticals Ltd Declines Again; Strong Momentum for Sellers - Post News (NASDAQ:GLMD)
www.kentuckypostnews.com - September 21 at 5:43 PM
News IconGalmed Pharmaceuticals Ltd (NASDAQ:GLMD) Receives Consensus Rating of “Buy” from Analysts - DailyQuint (NASDAQ:GLMD)
dailyquint.com - September 21 at 5:43 PM
smarteranalyst.com logoAnalysts Weigh in on Two Rising Biotech Stocks: Tobira Therapeutics Inc (TBRA) and Galmed Pharmaceuticals Ltd ... - Smarter Analyst (NASDAQ:GLMD)
www.smarteranalyst.com - September 21 at 5:43 PM
News IconWhat are Analysts Expecting for Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Earnings? - Frisco Fastball (NASDAQ:GLMD)
friscofastball.com - September 21 at 5:43 PM
News IconEarnings Take Center Stage; Analysts Weighing in on Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) - Frisco Fastball (NASDAQ:GLMD)
friscofastball.com - September 14 at 5:19 PM
streetinsider.com logoGalmed Pharma (GLMD) Names Dr. Liat Hayardeny as Chief Scientific Officer (NASDAQ:GLMD)
www.streetinsider.com - September 9 at 9:58 AM
News IconShares Gapping Up Before the Open: Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) - Post News (NASDAQ:GLMD)
www.kentuckypostnews.com - September 8 at 9:05 AM
News IconPlacing Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Shares Under the Microscope - Post News (NASDAQ:GLMD)
www.kentuckypostnews.com - September 8 at 9:05 AM
streetinsider.com logoGalmed Pharma (GLMD) Names Dr. Liat Hayardeny as Chief Scientific Officer - StreetInsider.com (NASDAQ:GLMD)
www.streetinsider.com - September 8 at 9:05 AM
publicnow.com logoGalmed Pharmaceuticals Announces the Appointment of Dr. Liat Hayardeny, Ph.D. MBA, as Chief Scientific Officer (NASDAQ:GLMD)
www.publicnow.com - September 8 at 9:05 AM
News IconShares Gapping Higher Pre-Market: Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) - Post News (NASDAQ:GLMD)
www.kentuckypostnews.com - September 3 at 9:52 AM
News IconShares Climbing Higher in Session: Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) - Post News (NASDAQ:GLMD)
www.kentuckypostnews.com - August 29 at 5:08 PM
News IconSell-side & Crowd View on Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) - Post News (NASDAQ:GLMD)
www.kentuckypostnews.com - August 25 at 10:16 AM
News IconEarnings According to Analysts for Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD)? - Post News (NASDAQ:GLMD)
www.kentuckypostnews.com - August 18 at 5:14 PM
News IconCrowd is Weighing in on Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) - Post News (NASDAQ:GLMD)
www.kentuckypostnews.com - August 18 at 8:12 AM
News IconGalmed Pharmaceuticals (GLMD) Q2-2016 Results (NASDAQ:GLMD)
www.bioportfolio.com - August 17 at 8:16 AM
finance.yahoo.com logoGalmed Pharmaceuticals reports 2Q loss (NASDAQ:GLMD)
finance.yahoo.com - August 4 at 8:08 AM
seekingalpha.com logoGalmed Pharmaceuticals' (GLMD) CEO Allen Baharaff on Q2 2016 Results - Earnings Call Transcript (NASDAQ:GLMD)
seekingalpha.com - August 4 at 8:08 AM
streetinsider.com logoGalmed Pharma (GLMD) Names Ran Oren as Chief Medical Officer - StreetInsider.com (NASDAQ:GLMD)
www.streetinsider.com - August 3 at 8:12 AM
finance.yahoo.com logoGalmed Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Business Update (NASDAQ:GLMD)
finance.yahoo.com - August 3 at 8:12 AM
breakingfinancenews.com logoMaxim Group announced (NASDAQ:GLMD) Galmed Pharmaceuticals Ltd, bumping down its target price to $9 earlier today (NASDAQ:GLMD)
breakingfinancenews.com - August 1 at 5:07 PM
barrons.com logo[$$] Galmed Could Double, Even With Reduced Outlook (NASDAQ:GLMD)
www.barrons.com - August 1 at 5:07 PM
publicnow.com logoGalmed Pharmaceuticals Announces the Appointment of Professor Ran Oren, M.D., as Chief Medical Officer (NASDAQ:GLMD)
www.publicnow.com - August 1 at 8:11 AM
finance.yahoo.com logo8:09 am Galmed Pharma names Ran Oren, M.D., as Chief Medical Officer (NASDAQ:GLMD)
finance.yahoo.com - August 1 at 8:09 AM
finance.yahoo.com logoGalmed Pharmaceuticals and SAMIL Pharm Sign a License Agreement for the Commercialization of Aramchol™ in Korea (NASDAQ:GLMD)
finance.yahoo.com - July 28 at 8:00 AM
publicnow.com logoGalmed Pharmaceuticals Second Quarter 2016 Conference Call and Webcast Scheduled for Wednesday, August 3rd, 2016 (NASDAQ:GLMD)
www.publicnow.com - July 27 at 8:48 AM
News IconEarnings Focus and Crowd Sourced Sentiment Review for Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) - TGP (NASDAQ:GLMD)
telanaganapress.com - July 22 at 8:09 AM
News IconTracking Analyst Ratings and Target Projections for: Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) - Press Telegraph (NASDAQ:GLMD)
presstelegraph.com - July 21 at 5:26 PM
News IconGalmed Pharmaceuticals Limited Ord (NASDAQ:GLMD) Sellers Increased By 8.56% Their Shorts - Consumer Eagle (NASDAQ:GLMD)
www.consumereagle.com - July 21 at 5:26 PM
News IconGalmed Pharmaceuticals Ltd. (NASDAQ:GLMD): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily (NASDAQ:GLMD)
www.engelwooddaily.com - July 20 at 8:07 AM
kcregister.com logoGalmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Increased 2.56%: Cognizant Technology Solutions Corporation ... - KC Register (NASDAQ:GLMD)
www.kcregister.com - July 18 at 5:28 PM
News IconTrading Performance and Target Watch for Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) - Press Telegraph (NASDAQ:GLMD)
presstelegraph.com - July 18 at 5:28 PM
News IconWere Analysts Bearish Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) This Week? - Consumer Eagle (NASDAQ:GLMD)
www.consumereagle.com - July 18 at 5:28 PM
News IconCould Galmed Pharmaceuticals Ltd Go Down? The Stock Formed Bearish Double Bottom Chart Pattern - Consumer Eagle (NASDAQ:GLMD)
www.consumereagle.com - July 14 at 5:21 PM
News IconCrowd Rating and Earnings Recap for Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) - Telanagana Press (NASDAQ:GLMD)
telanaganapress.com - July 14 at 5:21 PM
fiscalstandard.com logoBrokers Issue Average Price Target Of 19.00 On Galmed Pharmaceuticals Ltd. (GLMD) - Fiscal Standard (NASDAQ:GLMD)
www.fiscalstandard.com - July 14 at 5:21 PM
ftsenews.co.uk logoGalmed Pharmaceuticals Ltd. (GLMD) Updated Price Targets - FTSE News (NASDAQ:GLMD)
www.ftsenews.co.uk - July 14 at 5:21 PM
News IconGalmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Earnings Concentration and Analyst Target Watch - Engelwood Daily (NASDAQ:GLMD)
www.engelwooddaily.com - July 13 at 8:06 AM
News IconAre Analysts Bearish Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) After Last Week? - Press Telegraph (NASDAQ:GLMD)
presstelegraph.com - July 11 at 9:59 AM
fiscalstandard.com logoBroker Outlook For Galmed Pharmaceuticals Ltd. (GLMD) - Fiscal Standard (NASDAQ:GLMD)
www.fiscalstandard.com - July 7 at 8:03 AM
fiscalstandard.com logoBroker Outlook For The Week Ahead Galmed Pharmaceuticals Ltd. (GLMD) - Fiscal Standard (NASDAQ:GLMD)
www.fiscalstandard.com - July 5 at 9:56 AM
News IconDoes This Provide a Reason to Sell Galmed Pharmaceuticals Ltd? The Stock Has Formed Bearish Double Bottom - Press Telegraph (NASDAQ:GLMD)
presstelegraph.com - July 4 at 10:09 AM
streetinsider.com logoGalmed Pharma (GLMD), Weizmann Institute of Science Enter Research Collaboration - StreetInsider.com (NASDAQ:GLMD)
www.streetinsider.com - July 1 at 8:01 AM
streetinsider.com logoGalmed Pharma (GLMD), Weizmann Institute of Science Enter Research Collaboration (NASDAQ:GLMD)
www.streetinsider.com - June 30 at 5:31 PM
publicnow.com logoGalmed Pharmaceuticals and Weizmann Institute of Science to enter a research collaboration agreement to assess Aramchol™ effects on microbiome (NASDAQ:GLMD)
www.publicnow.com - June 30 at 8:21 AM
News IconGalmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Earnings Glance and Target Price Review - Engelwood Daily (NASDAQ:GLMD)
www.engelwooddaily.com - June 28 at 10:10 PM

Social

Galmed Pharmaceuticals (NASDAQ:GLMD) Chart for Wednesday, September, 28, 2016


Last Updated on 9/28/2016 by MarketBeat.com Staff